A novel ROS-responsive prodrug is provided. The prodrug utilizes a unique modified oxalate linker conjugated to 4-aminophenol, which can enhance the reaction kinetics for intracellular ROS within tumor tissues while keeping the modified oxalate backbone stable with amide bond under very low ROS level.
提供了一种新型的ROS响应型前药。该前药利用一种独特的改性
草酸连接物与4-
氨基苯酚偶联,可以增强肿瘤组织内细胞内ROS的反应动力学,同时在非常低的ROS
水平下保持改性
草酸骨架稳定的酰胺键。